新型溶瘤腺病毒研发子方向负责人

fanglinzhqf@163.com

方琳，博士，副教授，硕士生导师，江苏省“六大人才高峰”。主要从事靶向性溶瘤腺病毒介导的肿瘤治疗作用研究，主持国家自然基金、江苏省自然基金、省高校重大项目、中国博士后科学基金等项目，发表SCI论文14篇，获徐州市科技进步一等奖1项。2014-2015年作为访问学者于北卡罗来纳教堂山分校莱恩伯格肿瘤中心进修。

（一）近5年代表性论文

(1) Zhu Yufu; Zhang Xuefeng; Jin Jiaqi; Wang Xiaoqian; Liu Yang; Gao Jian; Hang Diancheng;Fang Lin; Zhang Hengzhu; Liu Hongmei ; Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction, Experimental Hematology & Oncology, 2025, 14: 1-19.

(2)Fang Lin; Tian Weiping; Zhang Chen; Wang Xueyan; Li Wanjing; Zhang Qi; Zhang Yuxin; Zheng Junnian ; Oncolytic Adenovirus-Mediated Expression of CCL5 and IL12 Facilitates CA9-Targeting CAR-T Therapy Against Renal Cell Carcinoma, Pharmacological Research, 2023, 189: 106701.

(3)Fang Lin; Yuan Sen; Wang Meng; Zhang Chen; Wang Xueyan; Li Hailong; Yang Jie; Li Wanjing; Sun Nan; Zhang Qi; Zhang Yuxin; Chai Dafei; Li Huizhong; Zheng Junnian; Wang Gang ; Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors, Cell Death Discovery, 2023, 9(1):328.

(4) Sun Nan; Zhang Jikai; Zhang Chen; Xie Tan; Zhang Zeyu; Wang Xueyan; Li Wanjing; Zhang Yi;Chen Zhaokai; Zheng Junnian;Fang Lin; Wang Gang ; Inhibition of human adenovirus replication by TRIM35-mediated degradation of E1A, Journal of Virology, 2023, 97(8): e0070023.

(5) Zhang Chen;Fang Lin; Wang Xueyan; Yuan Sen; Li Wanjing; Tian Weiping; Chen Jing; Zhang Qi; Zhang Yuxin; Zhang Qing; Zheng Junnian ; Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma, Molecular Therapy Oncolytics, 2022, 24: 14-25.

（二）发明专利

(1)王刚;郑骏年;方琳;柴大飞;李慧忠;杜红伟;田卉;一种靶向B7H3的CAR-T细胞的制备方法及应 用, 2022-7-15,中国, 201910168714.6

(2)郑骏年;张青;裴冬生;杨洁;李连涛;李慧忠;张宝福;方琳;赵铁锁;程乾;章龙珍;嵌合抗原 受体hFVIIL-CD8-OX40-CD3ζ及其用途, 2013-12-25,中国, ZL201210375577.1